S1P5 Inhibitors
2 drugsAbout S1P5
S1P5 is a G protein-coupled receptor (GPCR). It has emerged as a valuable target for drug development.
Currently, there is no genetic evidence directly linking S1P5 to specific diseases. However, the clinical success of S1P5-targeting drugs underscores its therapeutic potential.
Two FDA-approved drugs, ZEPOSIA and VELSIPITY, modulate S1P5. Both drugs are small molecules approved for immunology and other therapeutic areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Multiple Sclerosis, Relapsing-Remitting with only 1 trials.
- phase3 represents biological uncertainty with 50% completion.
Top Drugs
Bristol-Myers Squibb and Pfizer are the only companies with approved S1P5-targeting drugs.
The concentrated market suggests high barriers to entry or untapped potential for new players.
Drug Modality Landscape
Modalities
Routes of Administration
S1P5 is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
Clinical Trials 81 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 23 | 18 | 2 | 3 | 90% |
| Phase 2 | 31 | 19 | 7 | 5 | 73% |
| Phase 3 | 19 | 11 | 5 | 3 | 69% |
| Phase 4 | 8 | 2 | 3 | 3 | 40% |
Top Sponsors
By Modality
Drug Approval Timeline (2020 - 2023)
Relapsing forms of multiple sclerosis (clinically isolate...
The first drug was approved in 2020, and the most recent in 2023, spanning 4 years.
The recent approval suggests continued interest, but monitor for saturation as more drugs enter the market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 55 clinical trials targeting S1P5.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities